ella- ulipristal acetate tablet
cenexi hsc - ulipristal acetate (unii: yf7v70n02b) (ulipristal - unii:6j5j15q2x8) - ella is a progesterone agonist/antagonist emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure [see dosage and administration (2.1)] . e lla is not intended for routine use as a contraceptive. ella is contraindicated for use in the case of known or suspected pregnancy [see use in specific populations (8.1)]. risk summary ella is contraindicated for use during an existing or suspected pregnancy. no signal of concern regarding pregnancy complications was found in postmarketing studies [see data ]. isolated cases of major malformations in ella- exposed pregnancies were identified; however, the data are not sufficient to determine a risk for birth defects with inadvertent use of ella during pregnancy. miscarriage was reported in 14% of the known pregnancy outcomes; a rate that is similar
ella- ulipristal acetate tablet
redpharm drug, inc - ulipristal acetate (unii: yf7v70n02b) (ulipristal - unii:6j5j15q2x8) - ella is a progesterone agonist/antagonist emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure [see dosage and administration (2.1)] . e lla is not intended for routine use as a contraceptive. ella is contraindicated for use in the case of known or suspected pregnancy [see use in specific populations (8.1)]. risk summary ella is contraindicated for use during an existing or suspected pregnancy. no signal of concern regarding pregnancy complications was found in postmarketing studies [see data ]. isolated cases of major malformations in ella- exposed pregnancies were identified; however, the data are not sufficient to determine a risk for birth defects with inadvertent use of ella during pregnancy. miscarriage was reported in 14% of the known pregnancy outcomes; a rate that is similar
esmya
gedeon richter ltd - ulipristal acetate - leiomyoma - sex hormones and modulators of the genital system, - ulipristal acetate is indicated for pre-operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.ulipristal acetate is indicated for intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.
ella
cts ltd - ulipristal acetate - tablets - ulipristal acetate 30 mg - ulipristal - emergency contraception within 120 hours (5 days) of unprotected sexual intercourse or contraceptive failure.
ella
cts ltd - ulipristal acetate - tablets - ulipristal acetate 30 mg - ulipristal - emergency contraception within 120 hours (5 days) of unprotected sexual intercourse or contraceptive failure.
ulipristal acetate tablet
beximco pharmaceuticals ltd. - ulipristal acetate - tablet - 5 mg
karevonal 5mg tablets
sumar pharma ehf haukahlijð 5 102 reykjavik, iceland - ulipristal acetate - tablet - ulipristal acetate 5 mg - sex hormones and modulators of the genital system
ecinq 30 mg film-coated tablets
aspen healthcare malta limited 89, level 0 triq is-siggiewi siggiewi, sgw 2021, , malta - ulipristal acetate - film-coated tablet - ulipristal acetate 30 mg - sex hormones and modulators of the genital system
ella- ulipristal acetate tablet
rpk pharmaceuticals, inc. - ulipristal acetate (unii: yf7v70n02b) (ulipristal - unii:6j5j15q2x8) - ella is a progesterone agonist/antagonist emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. ella is not intended for routine use as a contraceptive. ella is contraindicated for use in the case of known or suspected pregnancy. [see use in specific populations (8.1 ).] risk summary ella is contraindicated for use during an existing or suspected pregnancy. no signal of concern regarding pregnancy complications was found in postmarketing studies [see data ]. isolated cases of major malformations in ella- exposed pregnancies were identified; however, the data are not sufficient to determine a risk for birth defects with inadvertent use of ella during pregnancy. miscarriage was reported in 14% of the known pregnancy outcomes; a rate that is similar to the u.s background rate for miscarriage. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized p
ella- ulipristal acetate tablet
a-s medication solutions - ulipristal acetate (unii: yf7v70n02b) (ulipristal - unii:6j5j15q2x8) - ella is a progesterone agonist/antagonist emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. ella is not intended for routine use as a contraceptive. ella is contraindicated for use in the case of known or suspected pregnancy. [see use in specific populations (8.1 ).] risk summary ella is contraindicated for use during an existing or suspected pregnancy. no signal of concern regarding pregnancy complications was found in postmarketing studies [see data ]. isolated cases of major malformations in ella- exposed pregnancies were identified; however, the data are not sufficient to determine a risk for birth defects with inadvertent use of ella during pregnancy. miscarriage was reported in 14% of the known pregnancy outcomes; a rate that is similar to the u.s background rate for miscarriage. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized p